HEPATITIS C
Clinical trials for HEPATITIS C explained in plain language.
Never miss a new study
Get alerted when new HEPATITIS C trials appear
Sign up with your email to follow new studies for HEPATITIS C, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
By submitting, you agree to our Terms of use
-
New hep c combo aims to match top therapy in phase 3 showdown
Disease control OngoingThis study tests a new two-drug combination, BEM/RZR, against an approved treatment, SOF/VEL, in 880 adults with chronic hepatitis C. The goal is to see if BEM/RZR can clear the virus as effectively and safely. Participants must not have taken prior HCV drugs and may have compens…
Matched conditions: HEPATITIS C
Phase: PHASE3 • Sponsor: Atea Pharmaceuticals, Inc. • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
Finger-Prick test could speed up hepatitis c treatment
Disease control OngoingThis study tests whether using a dried blood spot test (a simple finger prick) can help people with hepatitis C start treatment faster than the usual method that requires a blood draw. The trial involves 141 participants who work with a peer support program and telemedicine. The …
Matched conditions: HEPATITIS C
Phase: NA • Sponsor: Oregon Health and Science University • Aim: Disease control
Last updated Jun 27, 2026 13:03 UTC
-
Could hepatitis c positive lungs save lives? pilot study explores new transplant option
Disease control OngoingThis study tests whether lungs from donors with hepatitis C can be safely transplanted into people without the virus. The lungs are treated with a special machine to try to reduce the virus. If the recipient gets infected, they will be treated with standard antiviral medication. …
Matched conditions: HEPATITIS C
Phase: EARLY_PHASE1 • Sponsor: University Health Network, Toronto • Aim: Disease control
Last updated Jun 27, 2026 12:31 UTC
-
Peer support after prison may boost hepatitis c care
Disease control OngoingThis study tests whether peer mentors—people with similar experiences—can help individuals recently released from jail or prison get connected to Hepatitis C care and stay in treatment. About 80 participants will either receive a peer mentor or standard referral. The goal is to s…
Matched conditions: HEPATITIS C
Phase: NA • Sponsor: Montefiore Medical Center • Aim: Disease control
Last updated Jun 27, 2026 12:10 UTC
-
Second chance for hepatitis c cure: new trial tests best retreatment
Disease control ENROLLING_BY_INVITATIONThis study is for people in Pakistan with hepatitis C who did not get cured by their first treatment. It compares two different lengths of treatment with the drug Epclusa (12 weeks vs 24 weeks) to see which works better. About 318 adults will take part, and the goal is to find th…
Matched conditions: HEPATITIS C
Phase: NA • Sponsor: Queen Mary University of London • Aim: Disease control
Last updated Jun 27, 2026 07:58 UTC
-
Could hepatitis C-Positive kidneys be safe for transplant?
Disease control OngoingThis study tests whether kidneys from donors with hepatitis C can be safely transplanted into people without the virus. Recipients will take the antiviral drug Epclusa for 12 weeks to prevent or treat infection. The goal is to see if this approach is safe and effective, potential…
Matched conditions: HEPATITIS C
Phase: PHASE2 • Sponsor: Amit D Tevar, MD • Aim: Disease control
Last updated Jun 27, 2026 07:56 UTC
-
New drug combo may stop hepatitis c spread in organ transplants
Prevention OngoingThis study tests whether a short course of two drugs (glecaprevir/pibrentasvir and ezetimibe) can prevent hepatitis C infection in people who receive a kidney, heart, lung, or pancreas from a donor with hepatitis C. About 200 participants who are hepatitis C-negative will take th…
Matched conditions: HEPATITIS C
Phase: PHASE4 • Sponsor: Mayo Clinic • Aim: Prevention
Last updated Jun 27, 2026 08:04 UTC
-
10-Year hepatitis study aims to unlock secrets of liver disease
Knowledge-focused OngoingThis study follows people with chronic hepatitis B or C for up to 10 years to track how the disease changes over time. A smaller group with hepatitis B will receive the drug tenofovir alafenamide for 2 years to see if it reduces liver stiffness. Participants provide blood samples…
Matched conditions: HEPATITIS C
Sponsor: University of Maryland, Baltimore • Aim: Knowledge-focused
Last updated Jul 02, 2026 00:00 UTC